Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “buy” rating reaffirmed by analysts at Barclays PLC in a research report issued on Friday. They currently have a $122.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $103.00. Barclays PLC’s price objective points to a potential upside of 18.45% from the company’s current price.

Other equities research analysts have also issued reports about the company. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 target price (down from $118.00) on shares of Puma Biotechnology in a research report on Thursday, August 10th. Credit Suisse Group reaffirmed an “outperform” rating and set a $136.00 target price on shares of Puma Biotechnology in a research report on Wednesday, September 27th. BidaskClub lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $114.00 target price on shares of Puma Biotechnology in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Puma Biotechnology currently has an average rating of “Buy” and a consensus target price of $130.67.

Shares of Puma Biotechnology (PBYI) traded down $24.20 during mid-day trading on Friday, hitting $103.00. The company had a trading volume of 5,677,100 shares, compared to its average volume of 1,118,516. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $136.90.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same period in the prior year, the business posted ($1.11) earnings per share.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/barclays-plc-reiterates-buy-rating-for-puma-biotechnology-inc-pbyi/1698748.html.

In other news, SVP Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $100.09, for a total value of $1,501,350.00. Following the transaction, the senior vice president now directly owns 28,239 shares in the company, valued at approximately $2,826,441.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 22.70% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Wells Fargo & Company MN increased its holdings in shares of Puma Biotechnology by 154.5% in the 3rd quarter. Wells Fargo & Company MN now owns 58,551 shares of the biopharmaceutical company’s stock valued at $7,010,000 after acquiring an additional 35,541 shares during the period. Virginia Retirement Systems ET AL increased its holdings in shares of Puma Biotechnology by 121.8% in the 3rd quarter. Virginia Retirement Systems ET AL now owns 12,200 shares of the biopharmaceutical company’s stock valued at $1,461,000 after acquiring an additional 6,700 shares during the period. Legal & General Group Plc increased its holdings in shares of Puma Biotechnology by 13.1% in the 3rd quarter. Legal & General Group Plc now owns 11,865 shares of the biopharmaceutical company’s stock valued at $1,411,000 after acquiring an additional 1,375 shares during the period. TD Asset Management Inc. increased its holdings in shares of Puma Biotechnology by 39.1% in the 3rd quarter. TD Asset Management Inc. now owns 111,979 shares of the biopharmaceutical company’s stock valued at $13,409,000 after acquiring an additional 31,481 shares during the period. Finally, American International Group Inc. increased its holdings in shares of Puma Biotechnology by 8.1% in the 3rd quarter. American International Group Inc. now owns 19,262 shares of the biopharmaceutical company’s stock valued at $2,307,000 after acquiring an additional 1,441 shares during the period. Institutional investors and hedge funds own 80.98% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.